Search Articles

View query in Help articles search
e.g. John Smith or 0000-0001-6479-5330

Search Results (1 to 3 of 3 Results)

Download search results: CSV END BibTex RIS

Impact of Electronic Patient-Reported Outcomes on Unplanned Consultations and Hospitalizations in Patients With Cancer Undergoing Systemic Therapy: Results of a Patient-Reported Outcome Study Compared With Matched Retrospective Data

Impact of Electronic Patient-Reported Outcomes on Unplanned Consultations and Hospitalizations in Patients With Cancer Undergoing Systemic Therapy: Results of a Patient-Reported Outcome Study Compared With Matched Retrospective Data

It was shown that the use of a digital app or web-based system for symptom monitoring had reduced the number of emergency admissions and hospitalizations compared to a control group and had even extended (progression-free) survival times [8-11]. A reduction in the number of serious adverse events (SAEs) compared to the control group could also be attributed to the use of the digital application in 2 studies [9,12].

Andreas Trojan, Christian Kühne, Michael Kiessling, Johannes Schumacher, Stefan Dröse, Christian Singer, Christian Jackisch, Christoph Thomssen, Gerd A Kullak-Ublick

JMIR Form Res 2024;8:e55917

Download Citation: END BibTex RIS

Download PDF Download XML
Article has an altmetric score of 2

Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes

Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes

Biosimilars and reference biologics play a key role in the treatment of cancer and account for approximately 70% of the growth in costs of drugs from 2010 to 2015 [1]. Therefore, pricing is an important challenge for the medical society and biosimilars offer an attractive option for a value-based care environment with cost-saving potential [2].

Andreas Trojan, Sven Roth, Ziad Atassi, Michael Kiessling, Reinhard Zenhaeusern, Yannick Kadvany, Johannes Schumacher, Gerd A Kullak-Ublick, Matti Aapro, Alexandru Eniu

JMIR Cancer 2024;10:e54178

Download Citation: END BibTex RIS

Download PDF Download XML
Article has an altmetric score of 2

A Mobile App to Stabilize Daily Functional Activity of Breast Cancer Patients in Collaboration With the Physician: A Randomized Controlled Clinical Trial

A Mobile App to Stabilize Daily Functional Activity of Breast Cancer Patients in Collaboration With the Physician: A Randomized Controlled Clinical Trial

Our objective was to explore the impact of a mobile and Web-based app in both an unsupervised setting and a setting supervised by the treating physician. We conducted a prospective randomized trial and invited early breast cancer patients to continuously record their symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.0 via a novel electronic study device (mobile or Web app) and to also indicate their Eastern Cooperative Oncology Group (ECOG) Performance Status.

Marco Egbring, Elmira Far, Malgorzata Roos, Michael Dietrich, Mathis Brauchbar, Gerd A Kullak-Ublick, Andreas Trojan

J Med Internet Res 2016;18(9):e238

Download Citation: END BibTex RIS

Download PDF Download XML
Article has an altmetric score of 11